Abeona Therapeutics Files 8-K Report
Ticker: ABEO · Form: 8-K · Filed: Apr 22, 2024 · CIK: 318306
| Field | Detail |
|---|---|
| Company | Abeona Therapeutics Inc. (ABEO) |
| Form Type | 8-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
ABEONA files 8-K, check for updates.
AI Summary
On April 22, 2024, Abeona Therapeutics Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signifies an official update from Abeona Therapeutics to the SEC, potentially containing material information for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a change in risk.
Key Players & Entities
- ABEONA THERAPEUTICS INC. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 001-15771 (identifier) — Commission File Number
- 83-0221517 (identifier) — I.R.S. Employer Identification No.
- 6555 Carnegie Ave, 4th Floor Cleveland, OH 44103 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report (8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of April 22, 2024.
When was this report filed?
The report was filed on April 22, 2024.
What is the exact name of the reporting company?
The exact name of the registrant is ABEONA THERAPEUTICS INC.
In which state is Abeona Therapeutics Inc. incorporated?
Abeona Therapeutics Inc. is incorporated in Delaware.
What are the principal executive offices of Abeona Therapeutics Inc.?
The principal executive offices are located at 6555 Carnegie Ave, 4th Floor, Cleveland, OH 44103.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-04-22 16:05:33
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-015531.txt ( ) — 238KB
- abeo-20240422.xsd (EX-101.SCH) — 3KB
- abeo-20240422_lab.xml (EX-101.LAB) — 33KB
- abeo-20240422_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 22, 2024 ABEONA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-15771 83-0221517 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6555 Carnegie Ave , 4th Floor Cleveland , OH 44103 (Address of principal executive offices) (Zip Code) (646) 813-4701 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On April 22, 2024, Abeona Therapeutics Inc. issued a press release entitled "Abeona Therapeutics Provides Regulatory Update on Pz-cel." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press release dated April 22, 2024, entitled "Abeona Therapeutics Provides Regulatory Update on Pz-cel." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Abeona Therapeutics Inc. (Registrant) By: /s/ Joseph Vazzano Name: Joseph Vazzano Title: Chief Financial Officer Date: April 22, 2024